ASSESSMENT OF GENITAL AND URINARY TRACT INFECTIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH DAPAGLIFLOZIN

Document Type : Original Article

Authors

1 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tishreen University, Lattakia, Syria

2 Department of Internal Medicine (Endocrinology), Faculty of Medicine, Tishreen University, Lattakia, Syria

3 Department of Pharmaceutics and Pharmaceutical Technology، Faculty of Pharmacy, Tishreen University, Lattakia, Syria

Abstract

Several studies have shown that pharmacologically induced glucosuria with dapagliflozin increases the risk of developing urinary and genital tract infections (UTIs). The aim of this study is to assess the incidence of urinary and genital infections and to investigate risk factors in T2DM patients treated with dapagliflozin 5 and 10 mg. The study included 108 patients with type 2 diabetes, aged between 40-70 years, randomly selected from the outpatient of the Endocrinology Department at Tishreen University Hospital in Syria. 52 patients received once daily dapagliflozin (5 or 10 mg) as add-on therapy to oral antihyperglycemic drugs, and 56 patients treated with antihyperglycemic agents for 24 weeks. We compared patients with well-controlled diabetes to deny the effect of HbA1c on the incidence of urinary and genital infections.
We observed that treatment with dapagliflozin is associated with an increased risk of developing genital infections. There was no statistically significant increase in the incidence of urinary infections in patients treated with dapagliflozin. We identified gender and a previous history of genital infection as risk factors for genital infection. Long-term studies are still needed to determine association of dapagliflozin with an increased risk of UTIs.
 

Keywords

Bulletin of Pharmaceutical Sciences Assiut University
Volume 45, Issue 2
December 2022
Pages 953-965

Files

Share

How to cite

Statistics